Avelumab in First-line NSCLC (JAVELIN Lung 100)
- Conditions
- First Line Non-Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT02576574
- Brief Summary
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1214
- Male or female subjects aged greater than or equal to (>=) 18 years
- With Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry
- At least 1 measurable tumor lesion
- With histologically confirmed metastatic or recurrent (Stage IV) non-small cell lung cancer (NSCLC)
- With availability of a recently-obtained, formalin-fixed, paraffin-embedded (FFPE) tissue sample containing tumor (biopsy from a non-irradiated area preferably within 6 months) or a minimum number of 10 (preferably 25) unstained tumor slides cut within 1 week, and suitable for PD-L1 expression assessment
- Subjects must not have received any treatment for systemic lung cancer, and have an estimated life expectancy of more than 12 weeks
- Other protocol defined criteria could apply
- Subjects whose disease harbors a EGFR mutation, or anaplastic lymphoma kinase (ALK) rearrangement are not eligible.
- Other exclusion criteria include prior therapy with any antibody or drug targeting T cell coregulatory proteins, concurrent anticancer treatment, or immunosuppressive agents
- Known severe hypersensitivity reactions to monoclonal antibodies (Grade >= 3 NCI CTCAE v 4.03), history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma), and persisting toxicity related to prior therapy of Grade > 1 NCI-CTCAE v 4.03.
- Subjects with brain metastases are excluded, except those meeting the following criteria: brain metastases that have been treated locally and are clinically stable for at least 2 weeks prior to randomization, subjects must be either off steroids or on a stable or decreasing dose of <= 10 mg daily prednisone (or equivalent), and do not have ongoing neurological symptoms that are related to the brain localization of the disease.
- Other protocol defined criteria could apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Chemotherapy Paclitaxel - Chemotherapy Gemcitabine - Avelumab Weekly Avelumab Weekly - Avelumab Biweekly Avelumab - Avelumab Weekly Cisplatin - Chemotherapy Pemetrexed - Chemotherapy Carboplatin -
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) PFS is defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Overall Survival (OS) in Full Analysis Set (FAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Modified Full Analysis Set Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Overall Survival (OS) in Modified Full Analysis Set (mFAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) OS is defined as the time from randomization to the date of death, regardless of the actual cause of the participant's death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Modified Full Analysis Set Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Full Analysis Set Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Body Temperature Increase Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) The number of participants with changes from baseline in increased Body Temperature (degree Celsius \[°C\]) were reported by using criteria: Baseline temperature (temp.) less than (\<) 37°C, on treatment change \<1°C, 1 - \<2°C, 2 - \<3°C, greater than or equal to (\>=)3°C and missing; Baseline temp. 37 - \<38°C, on treatment change \<1°C, 1 - \<2°C, 2 - \<3°C, \>=3°C and missing; Baseline temp. 38 - \<39°C, on treatment change \<1°C, 1 - \<2°C, 2 - \<3°C, \>=3°C and missing; Baseline temp. 39-\<40°C, on treatment change \<1°C, 1 - \<2°C, 2 - \<3°C, \>=3°C and missing; Baseline temp. \>=40°C, on treatment change \<1°C, 1 - \<2°C, 2 - \<3°C, \>=3°C and missing; Baseline temp. missing, on treatment change missing.
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Weight Increase/Decrease Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) The number of participants with maximal on-treatment changes from baseline in Increase (Ic.)/Decrease (Dc.) in maximal weight were reported by using criteria: Ic./Dc. From baseline, on treatment (TR) change \<10 percentage (%), \>=10% and missing.
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Heart Rate Increase/Decrease Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) heart rate (HR) (beats per minute \[bpm\]) were reported by using criteria: Ic./Dc. BS HR \<100/\>=100 bpm, on treatment change =\<20 bpm, \>20 - =\<40 bpm, \>40 bpm and missing; Ic./Dc. BS HR missing, on treatment change missing.
Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Full Analysis Set Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Confirmed objective response was defined as the percentage of participants with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set Baseline, End of treatment (up to Week 283.9) EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAEs were those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period TEAEs included both serious TEAEs and non-serious TEAEs. Any AE that was suspicious to be a potential Immune-related adverse event (irAE) including infusion related reactions were considered AESIs. Number of participants with TEAEs and AESIs were reported.
Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Number of participants with shifts from Baseline values (Grade 0/1/2/3) to abnormal post-baseline values (shift to \>= Grade 4) were reported as per NCI-CTCAE, v4.03 graded from Grade 1 to 5. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death. Shifts in laboratory parameter (anemia, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, white blood cell count decreased, alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase increased, creatinine increased and Hyperglycemia) were reported.
Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.
Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment Baseline, End of treatment (up to Week 283.9) EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set Baseline, End of treatment (Week 283.9) EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set Baseline, End of treatment (up to Week 283.9) EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set Baseline, End of treatment (Week 283.9) EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set Baseline, End of treatment (up to Week 283.9) EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Respiration Rate Increase/Decrease Time from date of randomization up to data cutoff (assessed up to 71.5 months) The number of participants with maximal on-treatment (TR) changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) maximal Respiration Rate (RR) were reported by using criteria: Ic./Dc. BS RR \<20 breaths per minute (breaths/min), on TR change =\<5 breaths/min, \>5 - =\<10 breaths/min, \>10 breaths/min and missing. Ic./Dc. BS RR missing, on TR change missing. Ic./Dc. BS RR \>=20 breaths/min, on TR change =\<5 breaths/min, \>5 - =\<10 breaths/min, \>10 breaths/min and missing.
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Electrocardiogram (ECG) Parameters Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) ECG parameters included heart rate, PR interval, QRS interval, corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). PCSA criteria for abnormal value of ECG parameters: any heart rate \<= 50 bpm and decrease from baseline \>=20 bpm , any hear rate \>= 120 bpm and increase from baseline \>= 20 bpm; PR interval: \>= 220 milliseconds (ms) and increase from baseline \>= 20 ms; QRS interval \>= 120 ms; QTcF \> 450 ms, \> 480 ms, \> 500 ms, QTcF increase from baseline \> 30 ms and QTcF increase from baseline \> 60 ms; QTcB \> 450 ms, \> 480 ms, \> 500 ms, QTcB increase from baseline \> 30 ms and QTcB increase from baseline \> 60 ms.
Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Systolic Blood Pressure Increase/Decrease and Maximal Diastolic Blood Pressure Increase/Decrease Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) The number of participants with maximal on-treatment changes from baseline (BS) in Increase (Ic.)/Decrease (Dc.) Systolic Blood Pressure (SBP) and diastolic blood pressure (DBP) (millimeter of mercury \[mmHg\]) were reported by using criteria: Ic./Dc. BS SBP \<140 mmHg and \>=140 mmHg, on maximal treatment (TR) change =\<20 mmHg, \>20 - =\<40 mmHg, \>40 mmHg and missing; Ic./Dc. BS SBP missing, on maximal treatment (TR) change missing; Ic./Dc. BS DBP \<90 mmHg and \>= 90 mmHg, on maximal TR change =\<20 mmHg, \>20 - =\<40 mmHg, \>40 mmHg and missing; Ic./Dc. BS DBP missing on maximal TR change missing.
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. ECOG performance status was reported in terms of number of participants with baseline value vs worst post-baseline value (that is \[i.e.\] highest score).
Number of Participants With At Least One Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months) Serum samples were analyzed by a validated electrochemiluminesce immunoassay to detect the presence of antidrug antibodies (ADA). Samples that screened positive were subsequently tested in a confirmatory assay were tested for neutralizing antibodies (nAb). Number of participants with ADA or nAb positive results for Avelumab were reported.
Trial Locations
- Locations (347)
A.Z. Klina
🇧🇪Brasschaat, Belgium
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Arizona Center for Cancer Care
🇺🇸Surprise, Arizona, United States
St. Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
Hospital Bruno Born
🇧🇷Lajeado, Rio Grande Do Sul, Brazil
CHU Ambroise Paré
🇧🇪Mons, Belgium
University Cancer Institute
🇺🇸Boynton Beach, Florida, United States
ZNA Middelheim
🇧🇪Antwerpen, Belgium
Novant Health Oncology Specialists
🇺🇸Kernersville, North Carolina, United States
San Juan Oncology Associates
🇺🇸Farmington, New Mexico, United States
Calvary Mater Newcastle
🇦🇺Waratah, New South Wales, Australia
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
🇧🇷Curitiba, Paraná, Brazil
Hospital de Câncer de Barretos - Fundação Pio XII
🇧🇷Barretos, Sao Paulo, Brazil
University Hospital Centre "Sestre Milosrdnice"
🇭🇷Zagreb, Croatia
Vitkovicka nemocnice a.s
🇨🇿Ostrava - Vitkovice, Czechia
Krajska nemocnice Liberec, a.s.
🇨🇿Liberec, Czechia
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Hospital de Clínicas de Porto Alegre
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Clínico Universidad de Chile
🇨🇱Santiago, Chile
Nemocnice Na Plesi s.r.o.
🇨🇿Nova Ves pod Plesi, Czechia
Thomayerova nemocnice
🇨🇿Praha 4 - Krc, Czechia
General Oncology Hospital of Kifissia " Agioi Anargyroi"
🇬🇷Athens, Greece
Centre Hospitalier Intercommunal de Créteil
🇫🇷Creteil cedex, Val De Marne, France
MHAT for women's health - Nadezhda, OOD
🇧🇬Sofia, Bulgaria
Centre Antoine Lacassagne
🇫🇷Nice cedex 02, Alpes Maritimes, France
Hôpital Saint-Louis - Paris
🇫🇷Paris Cedex 10, France
University Clinic for Pulmonary Diseases
🇭🇷Zagreb, Croatia
CHU Angers - Hôpital Hôtel Dieu#
🇫🇷Angers Cedex 9, Maine Et Loire, France
Assaf Harofeh
🇮🇱Rishon Lezion, Israel
LungenClinic Grosshansdorf GmbH
🇩🇪Grosshansdorf, Schleswig Holstein, Germany
Petz Aladar Megyei Oktato Korhaz
🇭🇺Györ, Hungary
Zala Megyei Szent Rafael Korhaz
🇭🇺Zalaegerszeg, Hungary
CHU de Strasbourg - Nouvel Hôpital Civil
🇫🇷Strasbourg, Bas Rhin, France
Administradora Country S.A.
🇨🇴Bogotá, Colombia
Cork University Hospital
🇮🇪Cork, Ireland
General Hospital of Athens of Chest Diseases "SOTIRIA"
🇬🇷Athens, Greece
University General Hospital "Attikon"
🇬🇷Athens, Greece
Hôpital Cochin
🇫🇷Paris cedex 14, Paris, France
Metropolitan General Hospital
🇬🇷Athens, Greece
251 General Air Force Hospital
🇬🇷Athens, Greece
Soroka University Medical Center
🇮🇱Beer Sheva, Israel
Tolna Megyei Balassa Janos Korhaz
🇭🇺Szekszard, Hungary
Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.
🇨🇿Usti nad Labem, Czechia
Centre Hospitalier de la Croix Rousse
🇫🇷Lyon cedex 04, Rhone, France
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Baden Wuerttemberg, Germany
Sapir Medical Center, Meir Hospital
🇮🇱Kfar-Saba, Israel
Orszagos Koranyi Pulmonologiai Intezet
🇭🇺Budapest, Hungary
Orszagos Onkologiai Intezet
🇭🇺Budapest, Hungary
Institut Sainte Catherine
🇫🇷Avignon Cedex 9, Vaculuse, France
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
CHU Brest - Hôpital Morvan
🇫🇷Brest Cedex, Finistere, France
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz
🇭🇺Miskolc, Hungary
Azienda Ospedaliero Universitaria San Martino
🇮🇹Genova, Italy
Ajou University Hospital
🇰🇷Suwon-si, Gyeonggi-do, Korea, Republic of
Severance Hospital, Yonsei University
🇰🇷Seoul, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Tudogyogyintezet Torokbalint
🇭🇺Torokbalint, Hungary
Oncosalud
🇵🇪Lima, Peru
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
Osaka Medical College Hospital
🇯🇵Takatsuki-shi, Osaka-Fu, Japan
Presidio Ospedaliero Garibaldi Nesima
🇮🇹Catania, Italy
Yokohama Municipal Citizen's Hospital
🇯🇵Yokohama-shi, Kanagawa-Ken, Japan
Ulsan University Hospital
🇰🇷Ulsan, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
The Catholic University of Korea, Yeouido St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
National Cancer Center Hospital East
🇯🇵Kashiwa-shi, Chiba-Ken, Japan
Kobe City Hospital Organization Kobe City Medical Center General Hospital
🇯🇵Kobe-shi, Japan
Mount Lebanon Hospital
🇱🇧Beirut, Lebanon
Spitalul Clinic Municipal "Dr. Gavril Curteanu" Oradea
🇷🇴Oradea, Romania
Inje University Haeundae Paik Hospital
🇰🇷Busan, Gyeonggi-do, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Specialist
🇪🇸Barcelona, Spain
Hospital Garcia de Orta, EPE
🇵🇹Almada, Portugal
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
BHI of Omsk region "Clinical Oncology Dispensary"
🇷🇺Tomsk, Russian Federation
SBIH of Arkhangelsk region "Arkhangelsk Clinical Oncological Dispensary"
🇷🇺Arkhangelsk, Russian Federation
Irkutsk Regional Oncology Dispensary
🇷🇺Irkutsk, Russian Federation
Hospital Universitario Donostia
🇪🇸San Sebastian, Guipuzcoa, Spain
SBHI "Krasnoyarsk Regional Oncology Dispensary n.a. A.I. Kryzhanovsky"
🇷🇺Krasnoyarsk, Russian Federation
Johese Clinical Research
🇿🇦Pretoria, Gauteng, South Africa
Srinagarind Hospital
🇹🇭Muang, Khon Kaen, Thailand
Spitalul Militar de Urgenta "Dr.Constantin Papilian"Cluj -Napoca
🇷🇴Cluj-Napoca, Romania
Baskent University Adana Application and Research Center
🇹🇷Adana, Turkey
Emery Clinical Services
🇿🇦Alberton, Gauteng, South Africa
Chelyabinsk Regional Oncology Dispensary
🇷🇺Chelyabinsk, Russian Federation
Hospital Quiron Sagrado Corazon
🇪🇸Sevilla, Spain
CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU
🇺🇦Dnipro, Ukraine
National University Cancer Institute
🇸🇬Singapore, Singapore
RCI Sumy Regional Clinical Oncological Dispensary
🇺🇦Sumy, Ukraine
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital de Mataro
🇪🇸Mataro, Barcelona, Spain
SBHI of Kaluga Region "Kaluga regional clinical oncology dispensary"
🇷🇺Kaluga, Russian Federation
RBIH "Kursk regional clinical oncology dispensary" of Kursk Region Healthcare Committee
🇷🇺Kursk, Russian Federation
Hospital Universitario Mutua de Terrassa
🇪🇸Terrassa, Barcelona, Spain
Spitalul Judetean de Urgenta "Sf. Ioan cel Nou" Suceava
🇷🇴Suceava, Romania
RBIH "Ivanovo Regional Oncological Dispensary"
🇷🇺Ivanovo, Russian Federation
FSBHI Clinical research institute of phthisiopulmonology
🇷🇺St. Petersburg, Russian Federation
Complejo Hospitalario Universitario de Santiago
🇪🇸Santiago de Compostela, La Coruña, Spain
LLC Evimed
🇷🇺Chelyabinsk, Russian Federation
Hospital Regional Universitario de Malaga
🇪🇸Málaga, Spain
Medipol University Medical Faculty
🇹🇷Istanbul, Turkey
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
CI Chernivtsi RC Oncological Dispensary Bukovinian SMU Ch of Oncology and Radiology
🇺🇦Chernivtsi, Ukraine
SI S.P.Grygoriev Institute of Medical Radiology of NAMSU
🇺🇦Kharkiv, Ukraine
Lviv State Oncological Regional Treatment and Diagnostic Center
🇺🇦Lviv, Ukraine
Podilskyi Regional Oncological Center
🇺🇦Vinnytsia, Ukraine
Adana Numune Training and Research Hospital
🇹🇷Adana, Turkey
Cukurova University Medical Faculty
🇹🇷Adana, Turkey
ICO Girona - Hospital Universitari de Girona Dr. Josep Trueta
🇪🇸Girona, Spain
MD Anderson Cancer Centre
🇪🇸Madrid, Spain
Kartal Lutfi Kirdar Research and Training Hospital
🇹🇷Istanbul, Turkey
Inonu Uni. Med. Fac.
🇹🇷Malatya, Turkey
Siriraj Hospital
🇹🇭Bangkok, Thailand
Communal Non-profit Enterprise Regional Center of Oncology
🇺🇦Kharkiv, Ukraine
Kherson Regional Oncologic Dispensary
🇺🇦Kherson, Ukraine
Bakirkoy Dr. Sadi Konuk Teaching and Research Hospital
🇹🇷Istanbul, Turkey
Sakarya Traning and Research Hospital
🇹🇷Sakarya, Turkey
Namik Kemal University
🇹🇷Tekirdag, Turkey
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
🇹🇷Ankara, Turkey
Hacettepe University Medical Faculty
🇹🇷Ankara, Turkey
Okmeydani Research and Training Hospital
🇹🇷Istanbul, Turkey
Chelsea and Westminster Hospital
🇬🇧London, Greater London, United Kingdom
CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU
🇺🇦Ivano-Frankivsk, Ukraine
Treatment-Prevention Institution Volyn Regional Oncological Dispensary
🇺🇦Lutsk, Ukraine
Odesa Regional Oncologic Dispensary
🇺🇦Odesa, Ukraine
Acibadem Adana Hospital
🇹🇷Adana, Turkey
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
The Clatterbridge Cancer Centre
🇬🇧Wirral, Merseyside, United Kingdom
CI Kryvyi Rih Oncological Dispensary of DRC
🇺🇦Kryvyi Rih, Dnipropetrovsk Region, Ukraine
Kyiv City Clinical Oncological Center
🇺🇦Kyiv, Ukraine
Mersin University Medical Faculty
🇹🇷Mersin, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
🇵🇱Lodz, Poland
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie
🇵🇱Warszawa, Poland
Nevada Cancer Research Foundation
🇺🇸Las Vegas, Nevada, United States
University General Hospital of Heraklion
🇬🇷Heraklion, Greece
Euromedica General Clinic Thessaloniki
🇬🇷Thessaloniki, Greece
IMV-Pesquisa Cardiologica Sociedade Simples - HMD - COR
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hôpital privé Clairval
🇫🇷Marseille, Bouches-du-Rhône, France
NOB - Núcleo de Oncologia da Bahia
🇧🇷Salvador, Bahia, Brazil
Hospital São Vicente de Paulo
🇧🇷Passo Fundo, Rio Grande Do Sul, Brazil
Southend University Hospital
🇬🇧Westcliff on Sea, Essex, United Kingdom
Songklanagarind Hospital
🇹🇭Hat Yai, Songkhla, Thailand
Ospedale Mater Salutis
🇮🇹Legnago, Verona, Italy
Hôpital Nord - AP-HM Marseille#
🇫🇷Marseille cedex 20, Bouches-du-Rhône, France
King Chulalongkorn Memorial Hospital
🇹🇭Patumwan, Bangkok, Thailand
Rajavithi Hospital
🇹🇭Rajathevee, Bangkok, Thailand
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Nossa Senhora da Conceição
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
Liaoning Cancer Hospital & Institute
🇨🇳Shenyang, Liaoning, China
Linyi Cancer Hospital
🇨🇳Linyi, Shandong, China
Fundación Oftalmológica de Santander - FOSCAL
🇨🇴Floridablanca, Colombia
Clinique Victor Hugo - Centre Jean Bernard
🇫🇷Le Mans Cedex 02, Sarthe, France
National Cancer Center
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
Hospital Professor Doutor Fernando Fonseca, E.P.E.
🇵🇹Amadora-Lisbon, Portugal
Centro Hospitalar De Coimbra-CHUC
🇵🇹Coimbra, Portugal
Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
🇵🇹Porto, Portugal
S.C Gral Medical S.R.L
🇷🇴Bucuresti, Romania
Hospital Clinico Viña del Mar
🇨🇱Viña del Mar, Chile
Hospital Pablo Tobón Uribe
🇨🇴Medellín, Colombia
FALP - Fundación Arturo López Pérez
🇨🇱Santiago, Chile
IPS IMAT- Instituto Medico de Alta Tecnologia - Oncomedica S.A.
🇨🇴Monteria, Colombia
CEBROM - Centro Brasileiro de Radioterapia, Oncologia e Mastologia
🇧🇷Goiânia, Goiás, Brazil
The Moncton Hospital
🇨🇦Moncton, New Brunswick, Canada
North Estonia Medical Centre Foundation
🇪🇪Tallinn, Estonia
Spitalul Judetean de Urgenta "Dr. Constantin Opris" Baia Mare
🇷🇴Baia Mare, Romania
S.C Centrul de Oncologie Sf. Nectarie S.R.L
🇷🇴Craiova, Romania
Institutul Regional de Oncologie Iasi
🇷🇴Iasi, Romania
S.C Pelican Impex S.R.L
🇷🇴Oradea, Romania
Clinical Center Bezanijska Kosa
🇷🇸Belgrade, Serbia
Cheltenham General Hospital
🇬🇧Cheltenham, Gloucestershire, United Kingdom
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Clinica Santa Maria
🇨🇱Santiago, Chile
Centro de Investigaciones Clinicas Viña del Mar
🇨🇱Viña del Mar, Chile
Bank of Cyprus Oncology Center
🇨🇾Nicosia, Cyprus
S.C Policlinica de Diagnostic Rapid S.A
🇷🇴Brasov, Romania
Military Medical Academy
🇷🇸Belgrade, Serbia
National Cancer Centre
🇸🇬Singapore, Singapore
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan County, Taiwan
Maharaj Nakorn Chiang Mai Hospital
🇹🇭Muang, Chiang Mai, Thailand
Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos
🇵🇹Lisboa, Portugal
Spitalul Clinic Coltea
🇷🇴Bucuresti, Romania
Institute of Oncology and Radiology of Serbia
🇷🇸Belgrade, Serbia
Clinical Center Nis, Pulmonary Diseases Clinic
🇷🇸Gornji Matejevac, Serbia
Clinical Center Kragujevac
🇷🇸Kragujevac, Serbia
Institutul Oncologic "Prof. Dr. Al. Trestioreanu"
🇷🇴Bucuresti, Romania
Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei" Constanta
🇷🇴Constanta, Romania
S.C Radiotherapy Center Cluj S.R.L
🇷🇴Comuna Floresti, Romania
S.C Oncocenter Oncologie Clinica S.R.L
🇷🇴Timisoara, Romania
Clinical Center of Serbia
🇷🇸Belgrade, Serbia
Nemocnica s poliklinikou Sv. Jakuba, n.o. Bardejov
🇸🇰Bardejov, Slovakia
Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
🇸🇰Bratislava, Slovakia
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Institute for Pulmonary Diseases of Vojvodina
🇷🇸Sremska Kamenica, Serbia
Tan Tock Seng Hospital
🇸🇬Singapore, Singapore
Kaohsiung Chang Gung Memorial Hospital
🇨🇳Kaohsiung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Naresuan University Hospital
🇹🇭Muang, Phitsanulok, Thailand
Cape Town Oncology Trials Pty Ltd
🇿🇦Cape Town, Western Cape, South Africa
Complejo Hospitalario Universitario de Vigo
🇪🇸Vigo, Pontevedra, Spain
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Herning Sygehus
🇩🇰Herning, Denmark
Roskilde Sygehus
🇩🇰Roskilde, Denmark
Adana City Hospital
🇹🇷Adana, Turkey
Toyama University Hospital
🇯🇵Toyama-shi, Toyama-Ken, Japan
Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Txagorritxu
🇪🇸Vitoria, Spain
SBIH of Stavropol territory "Pyatigorsk Oncological Dispensary"
🇷🇺Pyatigorsk, Russian Federation
Kemerovo SPI Regional Clinical Oncology Dispensary
🇷🇺Kemerovo, Russian Federation
FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
🇷🇺Moscow, Russian Federation
Murmansk Regional Clinical Hospital named after Bayandin
🇷🇺Murmansk, Russian Federation
SBHI of Novosibirsk region "Novosibirsk Regional Oncological Dispensary"
🇷🇺Novosibirsk, Russian Federation
SAIH "Republican Clinical Oncological Dispensary of the Ministry of Healthcare of Republic Tatarstan
🇷🇺Kazan, Russian Federation
SBIH "Oncological Dispensary # 2" of the MoH of Krasnodar territory
🇷🇺Sochi, Russian Federation
SBIH "Leningrad Regional Oncological Dispensary"
🇷🇺Saint-Petersburg, Russian Federation
"Bio Eq" LLC
🇷🇺Saint-Petersburg, Russian Federation
SBIH of Yaroslavl region "Regional Clinical Oncological Hospital"
🇷🇺Yaroslavl, Russian Federation
The Queen Elizabeth Hospital
🇦🇺Woodville South, South Australia, Australia
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
University of Vermont Medical Center
🇺🇸Burlington, Vermont, United States
SBIH "Samara Regional Clinical Oncological Dispensary"
🇷🇺Samara, Russian Federation
FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
🇷🇺Saint-Petersburg, Russian Federation
Shato, Ead
🇧🇬Sofia, Bulgaria
Hospital Clínico San Borja Arriaran
🇨🇱Santiago, Chile
Clearview Cancer Institute
🇺🇸Huntsville, Alabama, United States
Christus Cancer Treatment Center
🇺🇸Shreveport, Louisiana, United States
South Georgia Medical Center
🇺🇸Valdosta, Georgia, United States
Sharp Memorial Hospital
🇺🇸San Diego, California, United States
Cookeville Regional Medical Center
🇺🇸Cookeville, Tennessee, United States
Lancaster Cancer Center
🇺🇸Lancaster, Pennsylvania, United States
Thompson Cancer Survival Center
🇺🇸Knoxville, Tennessee, United States
Coastal Bend Cancer Center
🇺🇸Corpus Christi, Texas, United States
Oncology Consultants, P.A.
🇺🇸Houston, Texas, United States
Northwest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
Albury Wodonga Regional Cancer Centre
🇦🇺Albury, New South Wales, Australia
St George Private Hospital
🇦🇺Kogarah, New South Wales, Australia
Coffs Harbour Health Campus
🇦🇺Coffs Harbour, New South Wales, Australia
Royal North Shore Hospital
🇦🇺St Leonards, New South Wales, Australia
Lismore Base Hospital
🇦🇺Lismore, New South Wales, Australia
Orange Health Service
🇦🇺Orange, New South Wales, Australia
Gold Coast University Hospital
🇦🇺Southport, Queensland, Australia
Gallipoli Medical Research Foundation Ltd
🇦🇺Greenslopes, Queensland, Australia
Ballarat Base Hospital
🇦🇺Ballarat, Victoria, Australia
South West Healthcare
🇦🇺Warrnambool, Victoria, Australia
Bendigo Hospital
🇦🇺Bendigo, Victoria, Australia
CRIO - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, Ceará, Brazil
Hospital de Caridade de Ijuí
🇧🇷Ijuí, Rio Grande Do Sul, Brazil
INCA - Instituto Nacional de Câncer
🇧🇷Rio de Janeiro, Brazil
Clínica de Neoplasias Litoral Ltda.
🇧🇷Itajaí, Santa Catarina, Brazil
Fundação Doutor Amaral Carvalho
🇧🇷Jaú, Sao Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto
🇧🇷São José do Rio Preto, Sao Paulo, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer
🇧🇷São Paulo, Sao Paulo, Brazil
CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
🇧🇷Santo Andre, Sao Paulo, Brazil
ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
🇧🇷São Paulo, Sao Paulo, Brazil
UMHAT "Sv. Ivan Rilski", EAD
🇧🇬Sofia, Bulgaria
Complex Oncological Center - Ruse, EODD
🇧🇬Ruse, Bulgaria
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
IRAM - Instituto de Radio Medicina
🇨🇱Santiago, Chile
Hospital Militar de Santiago
🇨🇱Santiago, Chile
Groupe Hospitalier Sud - Hôpital Haut-Lévêque
🇫🇷Pessac, Gironde, France
Centre Hospitalier de la Côte Basque
🇫🇷Bayonne, Pyrenees Atlantiques, France
CHU Besançon - Hôpital Jean Minjoz
🇫🇷Besancon Cedex, Doubs, France
University General Hospital of Patra
🇬🇷Patras, Greece
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Csongrad Megyei Mellkasi Betegsegek Szakkorhaza
🇭🇺Deszk, Hungary
Rabin Medical Center-Beilinson Campus
🇮🇱Petach Tikva, Israel
SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
🇭🇺Nyiregyhaza, Hungary
Fondazione Poliambulanza Istituto Ospedaliero
🇮🇹Brescia, Italy
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Kaplan Medical Center
🇮🇱Rechovot, Israel
Rambam Health Care Center
🇮🇱Haifa, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Seconda Università degli Studi di Napoli
🇮🇹Napoli, Italy
Azienda Ospedaliero Universitaria di Parma
🇮🇹Parma, Italy
Institute of Biomedical Research and Innovation Hospital
🇯🇵Kobe-shi, Hyogo-Ken, Japan
NHO Hokkaido Cancer Center
🇯🇵Sapporo-shi, Hokkaido, Japan
Kurume University Hospital
🇯🇵Kurume-shi, Fukuoka-Ken, Japan
Kanagawa Cancer Center
🇯🇵Yokohama-shi, Kanagawa-Ken, Japan
Kansai Medical University Hospital
🇯🇵Hirakata-shi, Osaka-Fu, Japan
Tokyo Medical University Hospital
🇯🇵Shinjuku-ku, Tokyo-To, Japan
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo-To, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Yonsei University Wonju Severance Christian Hospital
🇰🇷Wonju-si, Gangwon-do, Korea, Republic of
The Catholic University of Korea, St. Vincent's Hospital
🇰🇷Suwon-si, Gyeonggi-do, Korea, Republic of
CHA Bundang Medical Center, CHA University
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Rafik Hariri University Hospital
🇱🇧Beirut, Lebanon
Hotel Dieu de France Hospital
🇱🇧Beirut, Lebanon
American University of Beirut Medical Center
🇱🇧Beirut, Lebanon
Hammoud Hospital University Medical Center
🇱🇧Saida, Lebanon
ETZ Elisabeth
🇳🇱Tilburg, Netherlands
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
🇱🇹Kaunas, Lithuania
Martini Ziekenhuis
🇳🇱Groningen, Netherlands
Westfriesgasthuis - PARENT
🇳🇱Hoorn, Netherlands
Auckland City Hospital
🇳🇿Auckland, New Zealand
Dunedin Public Hospital
🇳🇿Dunedin, New Zealand
Palmerston North Hospital
🇳🇿Palmerston North, New Zealand
Waikato Hospital
🇳🇿Hamilton, New Zealand
Instituto Nacional de Enfermedades Neoplásicas
🇵🇪Lima, Peru
Tauranga Hospital
🇳🇿Tauranga, New Zealand
Wellington Hospital
🇳🇿Wellington, New Zealand
Clinica Internacional Sede San Borja
🇵🇪Lima, Peru
Instytut MSF Sp. o.o
🇵🇱Lodz, Poland
KO-MED Centra Kliniczne Lublin II
🇵🇱Lublin, Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna
🇵🇱Lodz, Poland
SP Zespol Gruzlicy i Chorob Pluc w Olsztynie
🇵🇱Olsztyn, Poland
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
🇵🇱Otwock, Poland
Centro Hospitalar e Universitário de Coimbra, E.P.E (CHC)
🇵🇹Coimbra, Portugal
Mazowiecki Szpital Onkologiczny
🇵🇱Wieliszew, Poland
Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Hospital CUF Porto
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
🇵🇹Porto, Portugal
Centro Hospitalar de São João, E.P.E.
🇵🇹Porto, Portugal
Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
🇵🇹Vila Nova de Gaia, Portugal
Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
🇵🇹Santa Maria da Feira, Portugal
Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj Napoca
🇷🇴Cluj Napoca, Romania
S.C Medisprof S.R.L
🇷🇴Cluj-Napoca, Romania
S.C Oncomed S.R.L
🇷🇴Timisoara, Romania
Medicinskiy gorod
🇷🇺Tyumen, Russian Federation
Tomsk Research Instutite of Oncology
🇷🇺Tomsk, Russian Federation
University of Pretoria Oncology Department
🇿🇦Pretoria, Gauteng, South Africa
Hospital Universitari Quiron Dexeus
🇪🇸Barcelona, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Memorial Antalya Hastanesi
🇹🇷Antalya, Turkey
Ege University Medical Faculty
🇹🇷Izmir, Turkey
Mount Vernon Hospital
🇬🇧Stevenage, Hertfordshire, United Kingdom
CCCH City Oncological Center SHEI Uzhgorod NU
🇺🇦Uzhgorod, Ukraine
Vinnytsia Regional Clinical Oncological Dispensary
🇺🇦Vinnytsia, Ukraine
Royal Stoke University Hospital
🇬🇧Stoke on Trent, Staffordshire, United Kingdom
SSZZOZ im. Dr Teodora Dunina w Rudce
🇵🇱Mrozy, Poland
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
🇵🇱Poznan, Poland
Izerskie Centrum Pulmonologii i Chemioterapii "IZER-MED" Spolka z o.o.
🇵🇱Szklarska Poręba, Poland
Treatment-Diagnostic Center of Private Enterprise of PPC Atsynus
🇺🇦Kropyvnytskyi, Ukraine
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Mercy Research
🇺🇸Oklahoma City, Oklahoma, United States
Kaiser Permanente Northwest
🇺🇸Portland, Oregon, United States
CEPON - Centro de Pesquisas Oncológicas de Santa Catarina
🇧🇷Florianópolis, Santa Catarina, Brazil
Cheyenne Regional Medical Center
🇺🇸Cheyenne, Wyoming, United States